BeOne Medicines
ONC
255 hedge funds and large institutions have $20.4B invested in BeOne Medicines in 2021 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 98 increasing their positions, 79 reducing their positions, and 38 closing their positions.
42% more capital inflows, than outflows
Capital inflows: $1.03B | Capital outflows: $727M
24% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 79
0.62% more ownership
Funds ownership: 54.5% → 55.12% (+0.62%)
0% more funds holding in top 10
Funds holding in top 10: 11 → 11 (0)
5% less funds holding
Funds holding: 269 → 255 (-14)
26% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 38
32% less call options, than puts
Call options by funds: $31.3M | Put options by funds: $46M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$190M |
| 2 |
Public Investment Fund
Al Aqiq District, Riyadh,
Saudi Arabia
|
+$162M |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$126M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$108M |
| 5 |
Temasek Holdings
Singapore
|
+$54.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$156M |
| 2 |
Rock Springs Capital Management
Baltimore,
Maryland
|
-$68.6M |
| 3 |
AG
Artal Group
Luxembourg
|
-$65.4M |
| 4 |
Capital Bank & Trust
Irvine,
California
|
-$53.7M |
| 5 |
Driehaus Capital Management
Chicago,
Illinois
|
-$52.7M |
ONC Hedge Fund Activity: Q3 2021 in Review
255 of the 5,733 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines (ONC) for Q3 2021, worth a combined $20.4B — up 6.9% from $19.1B a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of ONC and 28 opened new positions — a net loss of 10 holders — while 79 trimmed existing stakes and 98 added.
The largest buyer was Invesco, adding an estimated $190M. The largest seller was Fidelity Investments, cutting an estimated $156M.
- 255 institutional investors held BeOne Medicines (ONC) as of Q3 2021, down from 269 in Q2 2021.
- Funds reported $20.4B of BeOne Medicines stock for Q3 2021, up 6.9% quarter-over-quarter.
- 28 funds opened new BeOne Medicines positions in Q3 2021 and 38 closed out, a net change of -10 holders.
- The largest BeOne Medicines buyer in Q3 2021 was Invesco, an estimated $190M added.
- The largest BeOne Medicines seller in Q3 2021 was Fidelity Investments, an estimated $156M sold.
Based on aggregated 13F filings for Q3 2021.